# ImmunoGen

Source: https://onco.cc/companies/immunogen/  
OnCo record `immunogen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ImmunoGen made antibody-drug conjugates, antibodies that carry a strong drug to cancer cells. Its medicine Elahere treats ovarian cancer that has stopped responding to platinum chemotherapy. AbbVie bought the company in 2024.

## Summary

ImmunoGen, Inc. (formerly Nasdaq: IMGN), of Waltham, Massachusetts, developed antibody-drug conjugates. Its lead product, ELAHERE (mirvetuximab soravtansine-gynx), is a folate receptor alpha-directed ADC approved for platinum-resistant ovarian cancer. Its pipeline at the time of sale included IMGN-151, a phase 1 next-generation folate receptor alpha ADC, and pivekimab sunirine, a phase 2 CD123-directed ADC for blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer, with FDA Breakthrough Therapy designation in the relapsed or refractory setting. AbbVie agreed on 30 November 2023 to acquire ImmunoGen for USD 31.26 per share in cash, a total equity value of about USD 10.1 billion, and the merger was completed on 12 February 2024.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: ImmunoGen, Inc.; NASDAQ:IMGN
- HQ: Waltham, MA
- Type: biotech

## Notes

- AbbVie's own record is named 'AbbVie (incl. ImmunoGen, Capstan)'; this record holds the company itself, as capstan-therapeutics does. It is not Immunome (immunome), a different company with a similar name, which is why the two are cross-linked. Completion on 12 February 2024 is from ImmunoGen's 8-K of that date. No website or founding year is recorded.

## Sources

- AbbVie to acquire ImmunoGen (8-K exhibit 99.1, 30 November 2023): https://www.sec.gov/Archives/edgar/data/855654/000110465923122415/tm2331816d2_ex99-1.htm
- Form 8-K: completion of the merger (12 February 2024): https://www.sec.gov/Archives/edgar/data/855654/000110465924013712/tm245856d1_8k.htm

## Connected records

- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Immunome](https://onco.cc/companies/immunome/)
- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [CD123](https://onco.cc/targets/cd123/), [Folate receptor alpha](https://onco.cc/targets/folr1/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Pivekimab sunirine](https://onco.cc/drugs/pivekimab-sunirine/)

---
JSON: https://onco.cc/api/v1/entities/immunogen.json